QUOTE AND NEWS
StreetInsider.com  May 13  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Velti+plc+%28VELT%29+Posts+Q1+adj.-Loss+of+27cShare/8332656.html for the full story.
Cloud Computing  May 13  Comment 
Velti plc (Nasdaq: VELT), the leading global provider of mobile marketing and advertising technology and solutions, today announced financial results for the first quarter ended March 31, 2013. read more
StreetInsider.com  May 7  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/Velti+plc+%28VELT%29+Files+16.5M+Common+Shelf+for+Shareholders/8312370.html for the full story.
TechCrunch  Apr 19  Comment 
Mobile advertising firm Velti has released its monthly report on advertising impressions across its network. The iPad is far and away the leader when it comes to the tablet market, and is gradually chipping away share from the iPhone in terms of...
StreetInsider.com  Apr 19  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Velti+plc+%28VELT%29+Prices+16.5M+Ordinary+Share+Offering/8264649.html for the full story.
Cloud Computing  Apr 12  Comment 
Velti (NASDAQ: VELT), the leading global provider of mobile marketing and advertising technology, and BlueKai, today announced a mobile data partnership. As a result of the partnership, brands and agencies using BlueKai’s...
StreetInsider.com  Mar 27  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Velti+%28VELT%29+Launches+New+Velti+Media+Mobile+Ad+Network/8214052.html for the full story.
TechCrunch  Mar 18  Comment 
A lot of headlines have focused on the new Galaxy S4 as a potential iPhone challenger in terms of hype and mindshare, but mobile ad firm Velti offers a different perspective in its February summary of global exchange data from its network. The...
Wall Street Journal  Mar 13  Comment 
Among the companies with shares expected to trade actively in Wednesday's session are Express, Spectrum Pharmaceuticals and Velti.
Benzinga  Mar 13  Comment 
Spectrum Pharmaceuticals (NASDAQ: SPPI) dipped 35.40% to $8.03 in the pre-market session. Spectrum Pharmaceuticals expects sales of its drug Fusilev in the range of $10 million to $15 million for the first quarter and $80 million to $90 million...





You may also be interested in articles related to Velti (LON:VEL):
 


References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki